Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Didn’t noticed that, thanks for sharing
Wow , awesome Bro !
MRNA $$$$
Free Float reduced to 295M shares ! This will fly so much !
An Epstein-Barr Virus (EBV) vaccine clinical trial:
https://connect.trialscope.com/studies/d3d75c1e-070d-4736-87da-9127dc5187e6
MRNA stock is destined to follow the overall NASDAQ trend but we are moving up now. Finished the day above the 55 day exponential moving average. A good sign. The vaccination business is here to stay.
'Peer Reviewed' Study finds young Moderna jab recipients
Have a jaw-dropping 44X higher risk of developing myocarditis than the unvaccinated
By Julian Conradson
Published July 2, 2022 at 9:15pm
A peer-reviewed study from researchers in France has concluded that both the experimental Pfizer and Moderna vaccines significantly increase the risk of myocarditis compared to the unvaccinated.
While both mRNA therapies were found to be linked to the life-threatening heart condition, the Moderna jabs results were particularly shocking, especially among young adults, as researchers found the risk for myocarditis diagnosis following the Moderna jab was 44 times higher risk for individuals aged 18 to 24 years old.
As for Pfizer’s jab – which fared better, but not by much – the same age group experienced a 13x elevated risk for the serious condition, according to the study that was published last week in the scientific journal, “Nature.”
The new data mirrors several other recent studies that show a link between the treatments and numerous severe medical complications in addition to myocarditis, including, but not limited to, pulmonary embolism, blood clots, and even “sudden” death.
From the study:
[color=red]The largest associations are observed for myocarditis following mRNA-1273 vaccination in persons aged 18 to 24 years [Moderna 44x increase, Pfizer 13x increase][/color]. Estimates of excess cases attributable to vaccination also reveal a substantial burden of both myocarditis and pericarditis across other age groups and in both males and females.
The risk of myocarditis was substantially increased within the first week post vaccination in both males and females (Fig. 1 and Table S2). Odds-ratios associated with the second dose of the mRNA-1273 vaccine were consistently the highest, with values up to 44 (95% CI, 22–88) and 41 (95% CI, 12–140), respectively in males and females aged 18 to 24 years but remaining high in older age groups.
While young people experienced the worst reaction to the mRNA vaccines, researchers demonstrated, as has been done across multiple studies, that the risk was elevated across all age groups and it is highest around 1-week post-vaccination.
Overall, the Pfizer and Moderna jabs were associated with an 8x and a 30x increase in myocarditis risk, respectively, when compared to the unvaccinated, according to the study.
Individuals were also found to be at a greater risk of developing pericarditis, a similar and less severe, but still serious, heart condition. However, the increase was not nearly as high, at 2.9x for Pfizer and 5.5x for Moderna.
Conversely, the risk of myocarditis was also found to be elevated by 9x in those who have been infected with the Covid-19 virus. It is unclear whether or not vaccination status was factored in for this cohort.
From the study:
We perform matched case-control studies and find increased risks of myocarditis and pericarditis during the first week following vaccination, and particularly after the second dose, with adjusted odds ratios of myocarditis of 8.1 (95% confidence interval [CI], 6.7 to 9.9) for the BNT162b2 [Pfizer] and 30 (95% CI, 21 to 43) for the mRNA-1273 [Moderna] vaccine.
The association was stronger for the mRNA-1273 vaccine with odds-ratios of 3.0 (95% CI, 1.4–6.2) for the first dose and 30 (95% CI, 21–43) for the second. The risk of pericarditis was increased in the seven days following the second dose of both vaccines, with odds ratios of 2.9 (95% CI, 2.3–3.8) for the BNT162b2 vaccine and 5.5 (95% CI, 3.3–9.0) for the mRNA-1273 vaccine.
In other words, that ‘cure’ for the virus that’s nominally worse than the seasonal flu (99.95 recovery rate overall, 99.995% among children and young people) is more likely to put recipients into the hospital with a crippling heart condition than keeping them from being hospitalized with Covid.
And, not just a little more likely, either. Another recently published study found that for every one person the Pfizer vaccine keeps out of the hospital, five (!) people will suffer a “severe adverse reaction” – aka. a serious vaccine injury.
It’s worth pointing out that the 5 to 1 ratio is only related to the Pfizer jab and it’s 13x increase in myocarditis risk. At 44x, Moderna’s ratio of severe adverse events would likely be even greater.
~~~~~~~~~~~~~~~~~
JUST IN: FDA Advisors Recommend Emergency Authorization for Moderna’s Covid-19 Shot in Young Kids 6 Months to 5 Years of Age
https://www.thegatewaypundit.com/2022/06/just-fda-advisors-recommend-emergency-authorization-modernas-covid-19-shot-young-kids-6-months-5-years-age/
~~~~~~~~~~~~~~~~~
Unbelievably, the risk increase for the severe heart condition might even be higher than the data that the new French study shows, as researchers were limited to pulling information strictly from hospital discharge records. These records likely underscored the true number of myocarditis cases because they do not include those whose symptoms were not severe enough to be hospitalized or those who might have died suddenly before checking into a healthcare facility.
What’s more – the study only looked at those with one- and two-dose vaccinations and did not analyze the effect the booster jab had on the risk of myocarditis because it is not yet recommended for young adults in the country. This could also indicate that the true risk increase is higher, as other data has shown that with more mRNA doses, the higher the chance of developing complications.
One of the study’s authors, Dr. Sanjay Verma, even warned as much, stating that the excluded data “may yield even higher risk than reported.”
From Dr. Verma, who spoke with The Epoch Times about the French study:
“There have been reports (pdf) of autopsy-proven myocarditis after vaccination and anecdotal evidence of patients being dismissed by ER and never being hospitalized. Adjusting for these excluded subsets may yield even higher risk than reported in this study. Follow-up of the patients in this study was limited to one month after discharge. However, a previous cardiac MRI study found about 75 percent of patients with vaccine-associated myocarditis can have persistent MRI abnormalities 3–8 months after initial diagnosis.”
Dr. Verma also slammed the US Centers for Disease Control and Prevention (CDC) for misleading the public about the true incidence rate of myocarditis and its relation to the experimental vaccine. According to the expert cardiologist, the CDC has been “erroneously suggest[ing]” that the risk of myocarditis after Covid infection is higher than it is following mRNA injection – something his data, and others, have thoroughly disproven.
Nevertheless, the CDC and the public health ‘experts’ refuse to divert from the course.
Dr. Verma continued:
“Both SARS-CoV2 infection and COVID mRNA vaccines have been associated with myocarditis. Knowing the spike protein’s affinity to ACE2 receptors in the heart and spike protein’s injury to cardiomyocytes (cells of the heart), the association of myocarditis with SARS-CoV2 virus or spike protein-based mRNA vaccination was not entirely unexpected.
For the cases of myocarditis after SARS-CoV2, CDC uses officially confirmed PCR+ ‘cases,’ even though their own seroprevalence data demonstrates that far more people have been infected than officially conformed PCR+ ‘cases.’ For example, seroprevalence data as of Feb 21, 2022, reveals 75 percent (about 54 million) of all children have been infected compared to 12 million officially confirmed PCR+ ‘cases’ (i.e., the actual number of kids infected is 4.5 times greater than PCR+ ‘cases’). Therefore, calculating the risk of myocarditis after SARS-CoV2 infection, the rate noted by CDC would therefore need to be reduced by 4.5 times. Thus far, CDC has not adjusted its COVID-19 morbidity and mortality data accordingly.”
To download the new *peer-reviewed* French study, it can be found here.
https://www.thegatewaypundit.com/2022/07/ready-peer-reviewed-study-finds-young-moderna-jab-recipients-jaw-dropping-44x-higher-risk-developing-myocarditis-unvaccinated/
imo...Zob Whoblinked_o......has been forced into hiding>>>>MRNA
Could This Send Moderna's Stock Soaring Back to $400:
https://www.fool.com/investing/2022/06/30/could-this-send-modernas-stock-soaring-back-to-400/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article
imo... _ _ @!* _ _ <!!*! _ _ _! _ _ _(!@!) _ _ _POW!* _ _ _SCREECHINGmrna~
imo..there was never any organic pandemic dmfsb........MRNA
Possible; however, the COVID pandemic is only a little more than 2 years old, so it would seem to be early to detect an uptick in slowly progressing neurodegenerative diseases that resulted from long COVID.
But it also might be a result of long Covid, which is a real thing.
This might be a case of reverse causation. I.e., peeple who were more likely to develop neurogenerative diseases may have had weaker immune systems and been in worse overall health than the general population, making them more likely to catch COVID.
imo...
FDA advisory panel voted 19-2 to_include_an omicron component in a potential fall-2022 booster. The panel was not asked to vote on whether the booster should be monovalent or bivalent, but there was a clear preference among the panelists for bivalent. The panel was also not asked to vote on whether the omicron component of the booster should be B.1 or B.4/5, but there was a slight preference among the panelists for B.4/5.
TODAY: Vaccines and Related Biological Products Advisory Committee June 28, 2022 Meeting Announcement
https://www.fda.gov/advisory-committees/advisory-committee-calendar/vaccines-and-related-biological-products-advisory-committee-june-28-2022-meeting-announcement
COVID-19 positive patients at higher risk of developing neurodegenerative disorders, new study shows:
The study, which analyzed the health records of over half of the Danish population, found that those who had tested positive for COVID-19 were at an increased risk of Alzheimer's disease, Parkinson's disease, and ischemic stroke.
https://medicalxpress.com/news/2022-06-covid-positive-patients-higher-neurodegenerative.html
Moderna seeking Hong Kong regulatory approval for Omicron-targeted Covid-19 booster vaccine
https://www.scmp.com/news/hong-kong/health-environment/article/3183127/moderna-seeking-hong-kong-regulatory-approval
Exactly Bro
MRNA $$$$$
THE COMPANY is well-positioned for decades to come thanks to its cash hoard and rich pipeline. At current levels, this biotech stock can indeed make investors richer$$$$$$$$$$$
Moderna has the funds to advance its pipeline programs thanks to its success in the coronavirus market!
Expect the company to record key clinical wins in the next two years....
the flu, cytomegalovirus, Zika virus, and several forms of cancer.
LOL !
White flag here imo
MRNA $$$$$
The green flag: A booster that works
Moderna recently reported that its booster candidate offers "superior" performance against the omicron variant. The vaccine lifted a measure of neutralizing antibody activity eight-fold one month after vaccination, trial data show. This means the booster candidate handles the omicron variant even better than Moderna's coronavirus vaccine. And the candidate also protects against the original coronavirus. Moderna said this potential product is effective against omicron subvariants BA.4 and BA.5 too.
The biotech company is submitting the data to the U.S. Food and Drug Administration (FDA) for consideration. An FDA advisory committee is set to meet on June 28 to discuss whether it's necessary to update current vaccines for fall to target new strains -- or just stick with those original vaccines. Strong data from Moderna could weigh in favor of an update. This would be excellent news for the company. That's because Moderna appears to be closest to the finish line compared to rivals. Pfizer, too, is working on an updated shot -- but the big pharma player hasn't yet released data.
Covid-19 vaccines prevented nearly 20 million deaths in a year, study estimates
https://www.statnews.com/2022/06/23/covid19-vaccines-prevention-global-deaths/#:~:text=Health-,Covid%2D19%20vaccines%20prevented%20nearly%2020%20million,in%20a%20year%2C%20study%20estimates&text=Covid%2D19%20vaccines%20cut,in%20The%20Lancet%20Infectious%20Diseases.
9.42% % of Shares Held by All Insider
64.00% % of Shares Held by Institutions
70.66% % of Float Held by Institutions
Shares
Owned CEO 29,881,508
BIG COMPANY
CDC panel endorses Moderna two-dose COVID vaccine for kids ages 6 to 17
https://thehill.com/policy/healthcare/3534860-cdc-panel-endorses-moderna-two-dose-covid-vaccine-for-kids-ages-6-to-17/
MRNA manufacturing variant vaccine ahead of regulatory approval shows a lot of confidence they will get contracts from many countries. Again, the company has the capability to mass produce and is creating a moat by having a physical presence in key countries. Cannot emphasize enough that manufacturing and distributing is key and Moderna has the dollars to invest in this.
This is at least another 50 billion sales!!!!!!!!
Moderna's COVID-19 variant vaccine will be ready to ship in August as the company has been making shots ahead of approval, Chief Executive Stephane Bancel told Reuters on Wednesday, adding that the only bottleneck to supply was a regulatory one.
"Our goal is as early as August given we're going to file all the data in June, by the end of June... hopefully in the August timeframe, the vaccine is authorised," Bancel said in an interview.
"We can start shipping in the August timeframe. Some countries might be September, but that will really be a regulatory decision. Because what is (the) bottleneck now is regulatory. From a manufacturing standpoint, we are making the vaccine."
Dr Burton added that Moderna is due to file for regulatory approval for the variant jab 'within days' and this included the UK.
The stage is set. Time to rise. Mode RNA
Once again, confirms my belief that this company really knows what it's doing.
'We’ve talked with public health bodies in the UK, I think there is definite interest in 214 (the variant vaccine),' he said.
The new jab is a bivalent vaccine meaning it contains material from both the original Covid strain and the Omicron variant.
Moderna has already created hundreds of millions of doses of its vaccine, meaning if approved it could be rapidly distributed.
Responding to the Moderna data Professor Penny Ward, pharmaceutical expert at King's College London, welcomed the findings.
'The data suggest that the bivalent booster might confer greater protection against the BA.4 and BA.5 omicron strains than re-administering the original vaccine to increase protection across the population,' she said.
While she added the full data of the study needs to be seen, the new jab could prove a vital tool against Covid in the coming months.
'As we head towards the autumn with Omicron variants dominating the Covid infection landscape, it certainly makes sense to consider use of this new bivalent vaccine, if available, for the UK autumn Covid booster campaign,' she said.
Moderna has also said it is preparing the data from the trial for peer review.
The data comes as the NHS urged people who had not yet come forward for their spring booster to get their jab.
More than five million invited were sent out to people over the age of 75, care home residents or people aged 12 and over who have a weakened immune system.
If they ban abortion, then you can't give shots to kids!
One month after administration in previously vaccinated and boosted participants, a 50 µg booster dose of mRNA-1273.214 elicited potent neutralizing antibody responses against the Omicron subvariants BA.4 and BA.5 in all participants regardless of prior infection
$MRNA
MODERNA ANNOUNCES BIVALENT BOOSTER MRNA-1273.214 DEMONSTRATES POTENT NEUTRALIZING ANTIBODY RESPONSE AGAINST OMICRON SUBVARIANTS BA.4 AND BA.5
https://investors.modernatx.com/news/news-details/2022/Moderna-Announces-Bivalent-Booster-mRNA-1273.214-Demonstrates-Potent-Neutralizing-Antibody-Response-Against-Omicron-Subvariants-BA.4-And-BA.5/default.aspx
A reinfection red flag
Why a new report is so troubling:
For those thinking Covid is done.......
Hopefully Moderna is testing against BA.5
https://erictopol.substack.com/p/a-reinfection-red-flag
https://www.researchsquare.com/article/rs-1749502/v1
UK signs £1bn deal with Moderna for new vaccine centre:
The government is aiming to secure homegrown supplies of a technology that has proved a crucial weapon in the fight against Covid-19 and offers the prospect of transforming treatment for other conditions such as cancer.
https://www.ft.com/content/aab5de46-6a30-44fb-9e9d-08b915059b6f?ftcamp=traffic/partner/feed_headline/us_yahoo/auddev
$MRNA
White House is lying
Florida will not be supporting mRNA jabs for children
https://www.bitchute.com/video/gMr7VnW7In9H/ (4:48)
'No alignment' between CDC's statements and the truth
https://www.bitchute.com/video/XuT5SUO8OlO1/ (13:18)
Covid Israel, over 10 thousand infections in 24 hours: never so many since April
Following the growth of infections, the authorities have ordered hospitals to reopen the Covid wards that have been closed for months.
https://www.timesofisrael.com/israel-sees-over-10000-new-coronavirus-cases-highest-daily-number-since-april/
White House COVID adviser touts Moderna, Pfizer shots as ‘good choices’ for parents of kids under 5:
https://thehill.com/policy/healthcare/3529684-white-house-covid-adviser-touts-moderna-pfizer-shots-as-good-choices-for-parents-of-kids-under-5/
More than 800 days into the Covid-19 pandemic, 17 million US kids are finally eligible for vaccination!
$MRNA
imo...how much longer can MSM NOT TELL THE JABBED THIS IS A PUMPAND DUMP????????? MRNA
Smarter than the CDC?
Try to spot the unsafe vaccine
https://t.me/VigilantFox/4826
How many children die from the vaccine for each one we might save?
https://t.me/VigilantFox/4829
CDC Recommends COVID-19 Vaccines for Young Children:
https://www.cdc.gov/media/releases/2022/s0618-children-vaccine.html
Dr Paul thomas obviously made his conclusions long before doing his “study”. His anti-vaccination recommendations led to losing his license to practice medicine. Anybody accepting this kind of BS should not be posting information anywhere.
Comparing the vaccinated to the unvaccinated
https://www.bitchute.com/video/EXrEkBHHkLGN/ (6:38)
EU DRUGS WATCHDOG BEGINS REVIEW OF MODERNA’S VARIANT COVID VACCINE
https://www.pharmalive.com/eu-drugs-watchdog-begins-review-of-modernas-variant-covid-vaccine/
This stock is so manipulated !
But we will see much better times here sure !
CASH WINS imo !
GLTU ! GLTA!
Time to make some $$$$ here my friend
MRNA $$$$
Followers
|
176
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
13313
|
Created
|
12/10/18
|
Type
|
Free
|
Moderators DewDiligence Vexari axelvento |
2021 was a year of monumental impact and change for Moderna
Moderna entered 2021 with a strong cash position of approximately $5.25 billion. We have used this capital to invest in R&D and scale our development pipeline and manufacturing capabilities to maximize our impact on human health.
As we close our books for 2021, the company’s cash, cash equivalents and investments as of December 31, 2021, were more than $17 billion. We now have the resources to scale our investments and do even more to positively impact human health with mRNA medicines. This is just the beginning.
.
https://www.modernatx.com/newsroom/our-blog-coding-region/moderna-2021-shareholder-letter
Moderna is entering 2022 with a remarkable team poised to continue advancing mRNA vaccines and therapeutics into new areas for patients. We have a clear and exciting strategic path to do so, and a strong cash position.
Priority two is to go after the most important latent viruses and develop first-in-class vaccines against them. We want to protect our fellow human beings from suffering from the long-term damage caused by these viruses. Too many people have the quality of their health impacted because decades before, they were infected with a latent virus. We envision a world where vaccines against all the most important latent viruses are available to all.
Priority three is to bring to market therapeutics based on mRNA-encoded proteins, like our current pipeline in oncology, cardiology, rare genetic diseases and autoimmune diseases.
Priority four is to bring to market innovative therapeutics based on mRNA-encoded gene editing enzymes.
Moderna expects to enroll approximately 34,000 participants in multiple countries
RSV is a leading cause of severe respiratory illness in older adults (65+) and young children; there is no approved vaccine to prevent RSV
RSV illness in older adults results in an estimated $3 billion in annual medical costs in the U.S. each year
NOVEMBER, 18, 2021
https://investors.modernatx.com/news/news-details/2021/Moderna-Announces-First-Participant-Dosed-in-Phase-2-3-Study-of-its-mRNA-Respiratory-Syncytial-Virus-RSV-Vaccine/default.aspx
MODERNA ANNOUNCES POSITIVE DATA FROM PHASE 2 STUDY OF MRNA VEGF-A THERAPEUTIC IN PATIENTS UNDERGOING CORONARY ARTERY BYPASS GRAFTING SURGERY
Approval based on a comprehensive submission package including efficacy and safety data approximately six months after second dose
SPIKEVAX has received approval by regulators in more than 70 countries, including Canada, Japan, the European Union, the UK, Israel
807 million doses of Moderna's COVID-19 vaccine shipped globally in 2021; approximately 25% of those doses shipped to low- and middle-income countries
https://investors.modernatx.com/news/news-details/2022/Moderna-Receives-Full-U.S.-FDA-Approval-for-COVID-19-Vaccine-Spikevax/default.aspx
Q4 2021 revenues of $7.2 billion; GAAP net-income of $4.9 billion and GAAP diluted EPS of $11.29
Full year 2021 revenues of $18.5 billion; GAAP net-income of $12.2 billion and GAAP diluted EPS of $28.29
Moderna increased its 2022 signed advance purchase agreements to approximately $19 billion, with additional signed options of approximately $3 billion; numerous discussions ongoing with governments for the fall of 2022 and 2023
Moderna received full U.S. FDA approval for COVID-19 vaccine, Spikevax
Moderna announces new bivalent booster candidate (mRNA-1273.214) combining Omicron-specific booster candidate (mRNA-1273.529) and the Moderna COVID-19 vaccine (mRNA-1273)
Company now has 44 programs in development
Moderna announces a new $3 billion share repurchase plan
https://investors.modernatx.com/news/news-details/2022/Moderna-Reports-Fourth-Quarter-and-Fiscal-Year-2021-Financial-Results-and-Provides-Business-Updates/default.aspx
Facility to manufacture drug substance with opportunity for fill/finish and packaging capabilities
Moderna investing up to $500 million to produce up to 500 million doses each year for the African continent
Moderna will invest in building mRNA capabilities in Africa
https://investors.modernatx.com/news/news-details/2022/Moderna-Announces-Memorandum-of-Understanding-with-the-Government-of-the-Republic-of-Kenya-to-Establish-its-First-mRNA-Manufacturing-Facility-in-Africa/default.aspx
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |